Mexicor - instructions for use, dose, side effects, contraindications

AT 1 ml of the solution contains 50 mg of ethyl methyl hydroxypyridine succinate and Excipients: acid amber - 5,0 mg, disodium edetate - 0,1 mg, water for injections - up to 1,0 ml.

Description:Transparent colorless or slightly colored liquid.

Pharmacotherapeutic group:Antioxidant

ATX: & nbsp

N.07.X.X Other drugs for the treatment of diseases of the nervous system

Pharmacodynamics:

Mexicor® has antioxidant, antihypoxic, membrane-protective, nootropic, stress-protective, anticonvulsant, anxiolytic action.

The drug increases the resistance of the body to the effects of major damaging factors, to oxygen-dependent pathological conditions (shock, hypoxia and ischemia, cerebral circulation, alcohol intoxication and antipsychotic drugs (neuroleptics)).

The mechanism of action of Mexicor ® is due to the antihypoxic, antioxidant and membrane-protective action of ethylmethylhydroxypyridine succinate and succinic acid that make up its composition.

The drug improves the functional state of the ischemic myocardium with myocardial infarction, improves the contractile function of the heart, and also reduces the manifestations of systolic and diastolic dysfunction of the left ventricle.

The drug normalizes metabolic processes in the ischemic myocardium, reduces the necrosis zone, restores and / or improves electrical activity and contractility of the myocardium, and also increases its collateral blood supply, activating energy-producing processes in the ischemic zone and contributing to the preservation of cardiomyocyte integrity and maintenance of their functional activity.

Increases the antianginal activity of nitro drugs, improves the rheological properties of blood, reduces the effects of reperfusion syndrome in acute coronary insufficiency.

The drug improves blood flow to the brain and brain metabolism, improves microcirculation and rheological properties of blood, prevents the reduction of blood flow in the brain in the reperfusion period after ischemia. Has hypolipidemic effect, reduces the content of total cholesterol and low density lipoproteins. Mexicor® prevents the postischemic fall in the utilization of glucose and oxygen by the brain, prevents the progressive accumulation of lactate.

The drug inhibits the processes of lipid peroxidation, increases the activity of superoxide dismutase, increases the ratio of lipid-protein,improves the structure and function of the cell membrane. It modulates the activity of membrane-bound enzymes -calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase, receptor complexes (benzodiazepine, gamma-aminomethane, acetylcholine), which enhances their ability to bind to ligands, helps preserve the structural and functional organization of biomembranes, neurotransmitter transport and improve synaptic transmission. Mexicor® increases the content of dopamine in the brain.

Mexicor® causes an increase in the compensatory activity of aerobic glycolysis and helps to reduce the degree of inhibition of oxidative processes in the Krebs cycle under conditions of hypoxia with an increase in adenosine triphosphate (ATP), creatine phosphate and activation of the energy-synthesizing functions of mitochondria, and stabilization of cell membranes.

Pharmacokinetics:

With intravenous administration, the drug quickly (within 0.5-1.5 hours) passes from the bloodstream to the organs and tissues, in connection with which, its concentration in an unchanged form rapidly decreases. When administered intramuscularly in therapeutic doses, the maximum concentration of the drug in the blood plasma is reached after 30-40 minutes and is 2.5-3 μg / ml,while its metabolites are determined in the blood plasma for 7-9 hours.

Removal of the drug from the body occurs with urine in the glucuronoconjugate form, as well as in small amounts in unchanged form.

Indications:

The drug is used in complex therapy:

- Acute myocardial infarction (from the first day);

acute disorders of cerebral circulation;

- craniocerebral trauma, consequences of craniocerebral injuries;

- encephalopathy;

- syndrome of vegetative (neurocirculatory) dystonia;

- mild cognitive disorders of atherosclerotic origin;

- anxiety disorders with neurotic and neurosis-like conditions;

- relief of withdrawal syndrome with alcoholism with prevalence of neurosis-like and vegetative-vascular disorders;

- acute intoxication with antipsychotic drugs.

Contraindications:

Hypersensitivity to the drug, violations of the liver and kidneys, age under 18 years (efficacy and safety not established), pregnancy, the period of breastfeeding.

Dosing and Administration:

Intramuscularly (in / m) or intravenously (intravenously) (struino shi drip). With the infusion method of administration, the drug should be diluted in a 0.9% solution of sodium chloride.

Jet Mexicor® is injected slowly for 5-7 minutes, drip - at a speed of 40-60 drops per minute. The maximum daily dose should not exceed 1200 mg.

With acute myocardial infarction as part of complex therapy Meksikor® introduced into / in or / m for 14 days on standard therapy of myocardial infarction, comprising nitrates, beta-blockers, angiotensin converting enzyme (ACE) inhibitors, thrombolytic agents, anticoagulant and antiplatelet agents, as well as symptomatic agents indicated. In the first 5 days, to achieve maximum effect, the drug is preferably administered intravenously, in the next 9 days, Mexicocor® can be administered in / m. Intravenous drug produced by drip infusion slowly (to avoid side-effects), 0.9% sodium chloride solution or 5% dextrose (glucose) in a volume of 100 - 150 ml for 30-90 min. If necessary, a slow fluid iv injection of the drug, which lasts at least 5 minutes, is possible.

Administration of the drug (iv or IM) is carried out 3 times a day, every 8 hours.The daily therapeutic dose is 6-9 mg / kg body weight per day, single dose - 2-3 mg / kg body weight. The maximum daily dose should not exceed 800 mg, single dose - 250 mg.

In acute disorders of cerebral circulation (ischemic stroke) Mexicor ® is used in complex therapy in the first 10-14 days IV dropwise at 200-500 mg 2-4 times a day, then in / m 200-250 mg 2-3 times a day for 2 weeks.

In the future, if necessary, you can go to the drug inside (on the advice of a doctor).

In case of craniocerebral trauma and consequences of craniocerebral injuries

Mexicor® is used for 10-15 days in / in kalylevo 200-500 mg 2-4 times a day.

With discirculatory encephalopathy in the phase of decompensation Mexicor® is applied intravenously in a stream or drip in a dose of 200-500 mg 1-2 times a day for 14 days. Then in / m at 100-250 mg / day. in the next two weeks.

In the future, if necessary, you can go to the drug inside (on the advice of a doctor).

For the course of prophylaxis of dyscirculatory encephalopathy the drug is given in / m at a dose of 200-250 mg twice a day for 10-14 days.

With neurocirculatory dystonia, neurotic and neurosis-like states the drug is administered in / m at 50-400 mg per day for 14 days.

With mild cognitive impairment in elderly patients and with anxiety disorders the drug is used in / m at a dose of 100-300 mg per day for 14-30 days.

With abstinence alcohol syndrome Mexicor® is administered intravenously or intravenously at a dose of 200-500 mg 2-3 times a day for 5-7 days.

When acute intoxication with antipsychotic agents the drug is administered iv in a dose of 200-500 mg per day for 7-14 days.

Side effects:

With intravenous administration, especially jet, dry mouth and "metallic" taste, sensation of "pouring heat" in the whole body, sore throat and discomfort in the chest, a feeling of lack of air can occur. As a rule, these phenomena are due to the high rate of administration of the drug and are transient in nature.

Against the background of long administration of the drug, the following side effects may occur: from the gastrointestinal tract - nausea, flatulence; from the central nervous system - sleep disturbances (drowsiness or falling asleep).

Overdose:

Symptoms: sleep disturbance (insomnia), in some cases, drowsiness; at intravenous introduction in rare or infrequent cases insignificant and short-term (up to 1,5-2 hours) increase of arterial pressure.

Treatment: the development of overdose symptoms, as a rule, does not require the use of stoppers, these symptoms of sleep disturbance disappear on their own within 24 hours. In particularly severe cases, the use of one of the hypnotics and anxiolytic agents for oral administration (nitrazepam 10 mg, oxazepam 10 mg or diazepam 5 mg). When excessive blood pressure is increased, antihypertensives are used under the control of blood pressure.

Interaction:

Enhances the action of benzodiazepine anxiolytics, anticonvulsants (carbamazepine), anti-Parkinsonics (levodopa), nitrates. Reduces the toxic effects of ethyl alcohol.

Special instructions:

In case of acute myocardial infarction, acute (ischemic stroke) and chronic (dyscirculatory encephalopathy) disorders of cerebral circulation after completion of parenteral administration of the drug, it is recommended to continue the use of Mexocor® in the dosage form: capsules of 100 mg 3 times a day. The duration of therapy is determined by the doctor.

Form release / dosage:

Solution for intravenous and intramuscular injection, 50 mg / ml.

Packaging:

By 2 ml or 5 ml into ampoules from a light-protective glass with a color break ring or a colored break point. 5 ampoules are placed in a contour mesh package made of a polyvinylchloride film and aluminum foil or without foil (in a pallet).

2 contour cell packs with ampoules of 2 ml (FSUE "GosZMP", FGBU "RKNPK" of the Ministry of Health of Russia - EPMBP and BIOMED OJSC named after II Mechnikov) or 1, 2 or 4 contour squares with ampoules of 5 ml each (OJSC Biomed them. I.I. Mechnikov) together with instructions for use are placed in a pack of cardboard. For each ampoule, the label is self-adhesive.

Storage conditions:Keep in a place protected from light and inaccessible to children at a temperature not exceeding 25 FROM.

Shelf life:

3 years.

Do not use after the expiration date indicated on the package.

Terms of leave from pharmacies:On prescription

Registration number:P N002948 / 01

Date of registration:22.09.2008 / 24.04.2014

Expiration Date:Unlimited

The owner of the registration certificate:EcoFarmInvest, LLC EcoFarmInvest, LLC Russia

Manufacturer: & nbsp

STATE FACTORY OF MEDICAL PREPARATIONS, FSUE Russia

FIRMA FERMENT, LLC Russia

RUSSIAN CARDIOLOGICAL NPK FGU ROSMEDTEKHNOLOGIY - EXPERIMENTAL PRODUCTION OF MEDICAL AND BIOLOGICAL PREPARATIONS Russia

Representation: & nbspEcoFarmInvest Ltd. EcoFarmInvest Ltd. Russia

Information update date: & nbsp27.04.2018

Illustrated instructions

Instructions

Mexicor® (Mexicor®)